Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”, the “Company”) is pleased to announce that it has finalized an agreement with Neopharm Group (“Neopharm”) for an exclusive license (“License”) to market and sell CVac™, a…
Home | About Us | Companies | Partnering | Research | Corporate Citizenship | Careers | Newsroom | Contact | Legal Notice
All Rights reserved, Neopharm Group, Israel | Design by: VAZA | Developed by: The Shark Lady